Reports Positive Phase I Results For Actemra/Ro-Actemra Biosimilar
• By David Wallace
Generate a summary of this article
Listen to this article
Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.
Fresenius Kabi has announced progress in the development of its proposed biosimilar to Roche’s Actemra/Ro-Actemra (tocilizumab) anti-inflammatory treatment.
The German firm’s MSB11456 tocilizumab candidate – which it obtained through its September 2017 acquisition of Merck KGaA’s biosimilars business...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.